Drug Trial Radar · NCT06926829
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jun 25, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Apr 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in Japan
Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
EB-1020 (Centanafadine) 164.4 mgDrug
164.4 mg, capsule, oral, once daily, for 52 weeks
EB-1020 (Centanafadine) 328.8 mgDrug
328.8 mg, capsule, oral, once daily, for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline, week52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Maynds Tower Mental Clinic
Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.